Starfire

Starfire is a US-based company specializing in agentic commercial intelligence solutions for the life sciences sector, enhancing decision-making for biopharmaceutical companies through innovative technology. Starfire, founded in 2025 in Philadelphia, US, focuses on delivering advanced commercial intelligence solutions for the life sciences industry. The company has pivoted to enhance its offerings, aiming to streamline decision-making processes for pharmaceutical clients. In April 2026, Starfire raised an undisclosed amount of venture funding from new investor Redesign Health, which will support its initiatives in accelerating therapy commercialization through AI-driven workflows.

The firm has completed a total of 1 deal to date. Starfire specializes in agentic commercial intelligence solutions tailored for the life sciences sector. Its primary offering includes a platform that integrates agentic workflows for market access, patient analytics, and commercial strategy. This platform is designed to transform extensive consulting work into actionable insights for biopharmaceutical companies, assisting them in determining optimal strategies.

It features functionalities such as coverage architecture, formulary positioning, adherence analysis, referral mapping, and real-time recommendations, catering to clients across North America, Europe, and Asia-Pacific. Starfire generates revenue through a subscription-based model, enabling clients to access its commercial intelligence platform. The revenue framework includes standard subscription fees supplemented by charges for tailored analyses and bespoke services, ensuring ongoing client support and access to updated intelligence. This approach facilitates long-term relationships with pharmaceutical manufacturers, market access teams, and healthcare stakeholders.

Starfire plans to launch new products and enhance existing solutions aimed at accelerating therapy commercialization. The recent funding round in April 2026 will be utilized to develop automated, AI-driven workflows to further support pharmaceutical companies. Additionally, the company aims to expand its reach into new geographic regions, specifically targeting emerging markets in Asia-Pacific by the end of 2027.